{"id":"d93b203c-7022-55a8-922c-c3729a93ee8b","stable_key":"59b18080-c560-563d-abc5-bac4ee82a27c:ergothioneine-neuronal-verapamil","predicate":"abolishes","statement":"Verapamil abrogated ergothioneine protection in the human neuronal-cell study.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"138ec6e0-dc2f-5847-8eba-87c08553aa39","mechanism_event_label":"A transport-inhibiting drug weakened protection.","subject":{"id":"6267a621-1246-5518-919d-132ea338dcfd","slug":"verapamil","display_name":"Verapamil","entity_type_key":"small_molecule"},"object":{"id":"8814a595-1a82-51ba-95c8-e43f85edf0f1","slug":"human-ergo-neuronal-cytoprotection","display_name":"Ergothioneine-associated human neuronal cytoprotection","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"138ec6e0-dc2f-5847-8eba-87c08553aa39","stable_key":"59b18080-c560-563d-abc5-bac4ee82a27c:ergothioneine-neuronal-verapamil-event","event_type":"observed_relationship","label":"A transport-inhibiting drug weakened protection.","description":"Verapamil abrogated ergothioneine protection in the human neuronal-cell study.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6267a621-1246-5518-919d-132ea338dcfd","slug":"verapamil","display_name":"Verapamil","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8814a595-1a82-51ba-95c8-e43f85edf0f1","slug":"human-ergo-neuronal-cytoprotection","display_name":"Ergothioneine-associated human neuronal cytoprotection","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"939c92c3-50ea-5a4a-9654-8e3b94448132","slug":"ergothioneine","display_name":"L-Ergothioneine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"1509c925-fc5e-5a36-aa59-96bcc489965a","slug":"slc22a4","display_name":"Human ergothioneine transporter OCTN1 / SLC22A4","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"6-OHDA challenge with verapamil hydrochloride.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Verapamil is nonspecific; this experiment alone cannot prove exclusive SLC22A4 mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Ergothioneine collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"ergothioneine","display_name":"L-Ergothioneine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A transport-inhibiting drug weakened protection.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Ergothioneine-Mediated Neuroprotection of Human iPSC-Derived Dopaminergic Neurons. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38929132/ · DOI 10.3390/antiox13060693","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"8b699cba-59cd-546c-b7a8-b36faf1d1e59","evidence_kind":"source_excerpt","locator":"Lines 400-406","start_line":400,"end_line":406,"excerpt":"## ergothioneine-neuronal-verapamil\nA transport-inhibiting drug weakened protection.\nVerapamil abrogated ergothioneine protection in the human neuronal-cell study.\nModel: 6-OHDA challenge with verapamil hydrochloride.\nLimitations: Verapamil is nonspecific; this experiment alone cannot prove exclusive SLC22A4 mediation.\nEvidence access: Primary abstract\nErgothioneine-Mediated Neuroprotection of Human iPSC-Derived Dopaminergic Neurons. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38929132/ · DOI 10.3390/antiox13060693","model_system":"6-OHDA challenge with verapamil hydrochloride.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2f037d98-f3d0-5dbe-80d8-90b738f130d6","stable_key":"import-59b18080-c560-563d-abc5-bac4ee82a27c","title":"Ergothioneine: transport, redox chemistry and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"b6def8119f03cfabeec2fb55ba924340dc612e1dd42f05404201fa2b7ced5259","revision_id":"f88c38e6-ffb5-5a68-83ca-4610ca2c2df4","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}